How we know
Every link on this study, and who decided it
The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.
4 links0 made here, not in the record6 judgments2 judges (our rules as one)0 record changes seen
Claude Opus 5.5Our rules
Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.
Ado-Trastuzumab Emtansine
From the registry record2 judgments on this linkRole in the study, from the registry to what was judged
RegistryEntry “Trastuzumab Emtansine for Injection”the record gives no role
→judged=agreesHow the 2 judgments split100%of judgments with a known value say Comparator
Comparator · 2
All judgments on this study
| When | Link | Judge | Decision | State |
|---|---|---|---|---|
| Nov 2 | Ado-Trastuzumab Emtansine | Claude Opus 5.5 | Comparator | Current |
| Nov 2 | Trastuzumab | Claude Opus 5.5 | Not given | Current |
| Nov 14 | Breast Neoplasms | Our condition-kind rule | Finest filed term | Current |
| Nov 18 | Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Our role rule | Tested | Current |
| Nov 18 | Ado-Trastuzumab Emtansine | Our role rule | Comparator | Agrees |
| As of now | Breast Neoplasms | Our main-condition rule (R9) | Main condition | Current |